Phase III Data ENLIVEN Pexidartinib’s Prospects But Liver Tox An Issue?
Executive Summary
Phase III results for Daiichi Sankyo’s pexidartinib presented at ASCO provide new hope in a rare tumor type with no approved therapies, but hepatic toxicity also emerged as a safety issue in the study.
You may also be interested in...
Defining REMS Success An Unanswered Question For Daiichi's Pexidartinib
US FDA still deliberating on how best to measure success of the liver safety program for Daiichi's TGCT treatment, but REMS will probably assess both process and outcomes.
Daiichi's Pexidartinib Likely Needs REMS For Liver Safety Concerns
REMS with provider and pharmacy certification could help address hepatotoxicity worries for the tenosynovial giant cell tumor treatment, but Daiichi likely also will face clinical benefit questions during advisory committee review.
Asia Deal Watch: Junshi, Rxilient Form Joint Venture Around Toripalimab
Plus deals involving Biorchestra, Takeda/F-star, TaiGen/Joincare, Dr Reddy’s/Eris, Kaken/bitBiome, CJ Bioscience/4D Pharma, Ono/Macomics, Daiichi Sankyo/Zymeworks, Celltrion/Genuv and more.